SMARCA5 and neoplasm: We found that GC patients with high DNA binding activities of SMARCA5 and E2F3 and high phosphorylation of CCNL1 (at T67) and SMC4 (at S41) in tumor tissues associated with poor prognoses (Log-rank test, p < 0.05) (Supplementary Fig. 2c).